PMID- 24078718
OWN - NLM
STAT- MEDLINE
DCOM- 20140403
LR  - 20220309
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
VI  - 85
IP  - 3
DP  - 2014 Mar
TI  - Immune reactivity to neurofilament proteins in the clinical staging of 
      amyotrophic lateral sclerosis.
PG  - 274-8
LID - 10.1136/jnnp-2013-305494 [doi]
AB  - BACKGROUND: Neurofilament (NF) proteins detection in biological fluids as a 
      by-product of axonal loss is technically challenging and to date relies mostly on 
      cerebrospinal fluid (CSF) measurements. Plasma antibodies against NF proteins and 
      particularly to their soluble light chain (NF-L) could be a more practical 
      surrogate marker for disease staging in amyotrophic lateral sclerosis (ALS), an 
      invariably fatal and clinically heterogeneous neuromuscular disorder. 
      METHODOLOGY: We have used a recombinant neurofilament light chain (NF-L) protein 
      for the ELISA detection of antibodies against NF proteins in plasma samples from 
      a well-characterised cohort of ALS individuals (n:73). The use of an established 
      functional rating scale and of a recently proposed staging of disease progression 
      allowed stratification of the ALS cohort based on disease stage, site of onset, 
      survival and speed of disease progression. RESULTS: Antibody levels to NF 
      proteins in plasma were significantly higher in ALS individuals compared to 
      healthy controls (p<0.001). Higher NF plasma immunoreactivity was seen in 
      advanced ALS cases (stage IVA-B) compared to earlier phases of the disease 
      (p<0.05). There was no difference in anti-NF plasma antibodies between ALS 
      individuals treated with riluzole and untreated patients; although 
      riluzole-treated ALS cases with an earlier age of onset and with a shorter 
      diagnostic delay displayed higher anti-NFL antibody levels compared to untreated 
      ALS patients with similar features. CONCLUSIONS: Immunoreactivity to plasma NF-L 
      and homologous NF proteins is informative of the stage of disease progression in 
      ALS. The determination of NF antibody levels in plasma could be added to the 
      growing panel of disease-monitoring biomarkers in ALS targeting cytoskeletal 
      antigens.
FAU - Puentes, Fabiola
AU  - Puentes F
AD  - Neuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine 
      and Dentistry, Queen Mary University of London, , London, UK.
FAU - Topping, Joanne
AU  - Topping J
FAU - Kuhle, Jens
AU  - Kuhle J
FAU - van der Star, Baukje J
AU  - van der Star BJ
FAU - Douiri, Abdel
AU  - Douiri A
FAU - Giovannoni, Gavin
AU  - Giovannoni G
FAU - Baker, David
AU  - Baker D
FAU - Amor, Sandra
AU  - Amor S
FAU - Malaspina, Andrea
AU  - Malaspina A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130927
PL  - England
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
RN  - 0 (Antibodies)
RN  - 0 (Biomarkers)
RN  - 0 (Neurofilament Proteins)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Recombinant Proteins)
RN  - 0 (neurofilament protein L)
RN  - 7LJ087RS6F (Riluzole)
SB  - IM
MH  - Aged
MH  - Amyotrophic Lateral Sclerosis/*diagnosis/drug therapy/immunology
MH  - Antibodies/blood/immunology
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neurofilament Proteins/blood/*immunology
MH  - Neuroprotective Agents/therapeutic use
MH  - Recombinant Proteins
MH  - Riluzole/therapeutic use
OTO - NOTNLM
OT  - ALS
EDAT- 2013/10/01 06:00
MHDA- 2014/04/04 06:00
CRDT- 2013/10/01 06:00
PHST- 2013/10/01 06:00 [entrez]
PHST- 2013/10/01 06:00 [pubmed]
PHST- 2014/04/04 06:00 [medline]
AID - jnnp-2013-305494 [pii]
AID - 10.1136/jnnp-2013-305494 [doi]
PST - ppublish
SO  - J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):274-8. doi: 
      10.1136/jnnp-2013-305494. Epub 2013 Sep 27.